{
    "id": 13160,
    "fullName": "BIRC5 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "BIRC5 over exp indicates an over expression of the BIRC5 protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 332,
        "geneSymbol": "BIRC5",
        "terms": [
            "BIRC5",
            "API4",
            "EPR-1"
        ]
    },
    "variant": "over exp",
    "createDate": "10/22/2015",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4434,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LQZ-7F treatment in prostate cancer cells over expressing Birc5 (survivin) resulted in reduced cell survival and inhibition of tumor growth in culture and in xenograft models (PMID: 26744521).",
            "molecularProfile": {
                "id": 13340,
                "profileName": "BIRC5 over exp"
            },
            "therapy": {
                "id": 3506,
                "therapyName": "LQZ-7F",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4545,
                    "pubMedId": 26744521,
                    "title": "Effective Targeting of the Survivin Dimerization Interface with Small-Molecule Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26744521"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7842,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, YM155 reduced proliferation and induced cell-cycle arrest in anaplastic thyroid cancer cell lines with Birc5 (Survivin)-over expression in culture, and inhibited tumor growth and improved survival in a mouse model of metastatic anaplastic thyroid cancer (PMID: 25944801).",
            "molecularProfile": {
                "id": 13340,
                "profileName": "BIRC5 over exp"
            },
            "therapy": {
                "id": 3149,
                "therapyName": "YM155",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid gland cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6511,
                    "pubMedId": 25944801,
                    "title": "Inhibition of Survivin with YM155 Induces Durable Tumor Response in Anaplastic Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25944801"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 13340,
            "profileName": "BIRC5 over exp",
            "profileTreatmentApproaches": [
                {
                    "id": 7080,
                    "name": "YM155",
                    "profileName": "BIRC5 over exp"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}